<DOC>
	<DOCNO>NCT02761629</DOCNO>
	<brief_summary>This randomize , multi-center , Phase IV , comparative study ass efficacy safety combine peg-interferon alpha-2a ( Peg-IFN-Alpha-2A ) ribavirin therapy 48 72 week treatment 24 week follow-up participant Genotype 1 chronic hepatitis C ( CHC ) , co-infected human immunodeficiency virus type 1 ( HIV-1 ) .</brief_summary>
	<brief_title>Efficacy Safety Peg-Interferon Alpha-2a Plus Ribavirin Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Serological evidence chronic hepatitis C infection antihepatitis C virus ( HCV ) test Detectable HCVribonucleic acid ( RNA ) plasma level test Roche AMPLICOR HCV ( &lt; 50 International Units per milliliter [ IU/mL ] ) ( qualitative test ) Chronic liver disease consistent infection CHC Compensated liver disease ( ChildPugh Grade A ) Serological evidence infection HIV1 test , antiHIV1 HIV1 RNA detection Negative pregnancy urine blood test ( woman childbearing age ) ; additionally , men woman childbearing potential must agree use two effective form contraception treatment 6 month end treatment Pregnant nursing woman male partner pregnant woman Prior therapy interferon ( IFN ) ribavirin investigational medication less equal ( &lt; /= ) 6 week first dose study drug History evidence medical condition associate chronic liver disease HCV Active opportunistic infection associate HIV / cancer require systemic therapy History significant illness investigator 's opinion , could result participant 's inability meet Protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>